If you stick your head in the sand, keep your mouth closed.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Dilly Dilly
I think things are falling into place and we're closer to good news with the phase III. The next 2-3 months should be 'interesting'! Of course, time can be exhausting for long time longs like myself. But I should remind myself that many patients need Dcvax and are more in need. But I think It's a very good thing that phase III wasn't stopped too early. So I think that we are 'finally' getting there, my interpretation. Good day!
Thanks Flipper. Throwing you a herring.
Virtually of course.
Certain things have to happen for LP to access and/or collect on the potentially exercisable options/warrants she controls. If she could, she’s up to about 110 million or so, IMO.
Remember, some of her shares accelerate fully for certain events like sale of company and/or filing a BLA and/or trial success of phase II or phase iii trial.
Some shares don’t become available unless vote to authorize share increase.
Some shares don’t become available unless she collects on the loan.
A “win” based on one of the above events would likely lead to unlocking all but 17 million potential shares. This is all my opinion.
They would be considered closely held shares, and might not add to the float a great deal unless there was a sale of the company.
Question for anyone, anyone? Bueller?
Anyone have any idea now, with the sale of Cognate, bonuses, extra shares, warrants and all... How many shares does Linda now have?
I assume these are now all hers personally, since Cognate is no longer in the picture.
TIA
Exactly!
Averaged down to .48
Didn't like it, but had to be done.
Yes. If your like me then you bought shares at $7 range so it’s not like we have any choice but average down and hope for approval. It’s not the best position to be in but I believe in MD Liau. Just suspect about management but hoping they pull it around.
Definitely not true. Take a look at the analytics of his posts.
Very successful.
But he pump everyday but only on twitter which a little to no effect at all
Gotcha. Thanks for the clarification.
I'm tired of waiting too... having been in this for over 6 years.
Not disrespecting anyone and sorry if I cane out that way. Only meant to say he has been rather quiet lately instead of the days to weeks messages he has been giving for sometime. I feel that he does know more than the average trader and I get a good bit of information from him. I’m just sick of this waiting game. I’ve been in it for over 4 years
Just like your posts are in desperation for fear of NWBO being a success.
You take his tweets as desperation? I take them as excitement about things to come. He is a guy who when he knows something is good, he wants to share it.
Sure beats being an angry, pessimistic human being. Just sayin.
Who wouldn’t if they had their life savings in this thing. His tweets are overkill of desperation then if he is that confident!
Not strange at all.
Talk to him all the time and met him at ASM.
Really good guy. Still long NWBO, like me.
Not a pumper, just a guy who wants the best for patients and his pocketbook.
Unlike many here who only want to label people... put them down so they can feel superior. SMH
In other news chris lacoursier hasn’t tweeted since March 8.... kinda strange that he hasn’t pumped in a while.
Wasn't overlooked by me.
After being invested for over 4 years this was kind of shocking to me when Linda said this and that this information never was known before.
If I had known this, I would not have stayed invested from back when I initially did and continually add to my position. I would have waited, knowing that final data wouldn't come until now.
This one piece of information felt like a betrayal to me as there was never any chance of this stock taking off until the final data collection.
This is the carrot in front the horse kind of sh*t that irritates me about management. No worries... 4-6 weeks all our questions will be answered (and free beer tomorrow).
I thought this portion from the ASM was somewhat overlooked, so I decided to post it again with some highlighting.
Quote:When we do a data collection, it's about a 3 month process to collect an update. The independent CRO sends physical staff to all of the sites. We have some 80 sites in this trial. A breathing, human person looks at the [patient] files at each hospital and looks at the numbers and compares them to the central database. The central database is kept by an independent data company that's separate from the CRO. And, by the way, the company (NWBO) doesn't do any of this. That process generates what are called queries. Anything where a piece of data is missing or inconsistent, is a query. A data collection process can generate several thousand queries. All of them have to be resolved. Only then do you have a clean data set from the collection. Once you have a clean collection, then it goes to the independent statisticians who then tabulate it.
So you have the CRO making the in person visits, you have the queries getting resolved and the independent data company holding the clean data set, and you have the independent statisticians tabulating it. It takes about three months to do that process. We have done it once each for the last three years. We have not made any announcements about the spring of this year, but, it would be a, uh, reasonable thought that there might be a similar cycle in the spring of this year. -- Linda Powers
I'm just waiting for the one armed man to appear.
The plot thickens!
No.
Could you explain and elaborate on what rumors led you to this opinion?
I believe the article is done too.
I believe it was submitted in the fall as Linda said too.
I also believe it is 3-6 months from submission until publication, provided it is not rejected for modifications.
I also believe it has been rejected at least one time. Just my opinion from rumors I have heard.
Don't know anything as fact. Just like anyone else.
It's all Hofstadter's fault.
Hofstadter's law is a self-referential time-related adage, coined by Douglas Hofstadter and named after him. Hofstadter's Law: It always takes longer than you expect, even when you take into account Hofstadter's Law.
Imho I believe Dr.Bosch, & Dr.Liau, paper is done, submitted and waiting to be published. I believe them. Thanks for your updates.
Whatever. She said damn, she didn't say damn.
She threw her arms up in the air in apparent exasperation. Did you get that on tape? Or maybe somebody video recorded it.
Who really cares? Does anyone on this board have anything better to do with their time than to argue syntax on comments? Or whether the article (or damn article) comes out 9 months from the day or a day later or a month later?
Yeah, Linda and Les are not to be trusted. Oh... wait...maybe they are? Maybe not? Yes they are.. no they aren't.
Did you record it? No. Please review detailed ASM notes in calendar.
Take it for what you will.
I was there. You weren't. I am just calling it the I see it.
B.S.
Instead, nine months is nine months. If they pulll more “planned” events, just like they did the Cognate sale, before the publication, it will be obvious what they are doing.
4 of 5 people not being able to count to nine months would be funny.
(And happy, the guy obviously had a recorder. No plausible deniability).
You can't tell the date from what she said.
I interpreted her comment to be 3-6 months from submission which was "in the fall". She said they spent the summer writing the article.
So a set date is impossible to tell in my opinion Flip.
After March 5, 2018, the publication is late in my book. (If it has not been published in the meantime.)
Quote:When we made the announcement at ASCO [June 5, 2017], that was the beginning of the publication pathway. If you're familiar with top-tier scientific journals, it's not unusual for it to take 6-7-8-9 months. -- Linda Powers , January 21, 2018 at ASM
Others can interpret what they want. I have one interpretation of the above quote.
Mmmm... Bacon. Cure to all the worlds problems.
I sure can. 4-6 weeks. And it will have a side of bacon.
Friday.
What’s March 9?
Very nice Senti. And with a little wit.
Here’s Adam’s article in it’s entirety, and next, I’m going to pick it apart.
Quote:Maryland-based company developing an experimental brain cancer treatment called DCVax, said that it had collected enough clinical trial data to determine whether its vaccine could delay the growth of tumors longer than standard of care.
In other words, the randomized, controlled study was ready to be analyzed.
NWBO never said that. Yes, they did state they had reached 248 PFS events - which was the “threshold” for the trial; however they also stated in their February 6, 2017 PR that they would continue to accumulate PFS events as the trial continued. That does not sound like it was ready to be analyzed, as much as some of us would like some analysis.
https://www.nwbio.com/nw-bio-announces-lifting-clinical-hold-dcvax-l-phase-iii-trial-fda-progression-free-survival-events-reached-overall-survival-events-not-yet-reached/
By the way, "threshold" is defined as: the magnitude or intensity that must be exceeded for a certain reaction, phenomenon, result, or condition to occur or be manifested.
Quote:One year later, Northwest Bio’s pivotal Phase 3 study remains open. The DCVax data have not been analyzed or disclosed. Institutional investors have largely abandoned the company. Its stock trades for pennies on an over-the-counter exchange. And development on its only other drug has been stalled for years due to lack of funding.
The company stated at the ASM (which Adam also cites in his article) that they have analyzed the data every spring. What he is only correct about is that they haven’t disclosed it.
Quote:Even by the most lenient standards, investigators involved in Northwest Bio’s trial and outside cancer experts say that its reporting delay has been extraordinary and casts doubt on the study’s outcome.
You’ll see later how no investigators involved in the trial state what he states here. And so who are these so-called experts stating this is extraordinary who ARE investigator’s in the trial? There are none. There are just two “outside cancer experts.”
Quote:“The total lack of transparency is really unique. We work with a lot of companies and have a big clinical trial program, but I have never seen anything like this,” said Dr. Don O’Rourke, a neurosurgeon and brain tumor expert at Penn Medicine in Philadelphia. O’Rourke’s hospital enrolled brain tumor patients into Northwest Bio’s study.
Guess what, Dr. Don O’Rourke is NOT an investigator. The hospital he is affiliated with did enroll patients, however. But Dr. Don O'Rourke is chasing a different treatment modality in GBM - he is the the lead investigator on a… drum roll please… CAR T trial for glioblastoma (ahhhh). In fact, he’s loading the CAR Ts with EGFRv3 (double ahhhh).
Let's see if that doesn’t color every quote for you that he makes thereafter.
Dr. Don and CAR-T:
https://www.pennmedicine.org/news/news-releases/2016/april/pennled-team-presents-results
Quote:Biotechs generally enjoy some latitude when it comes to the timing of closing trials and reading out the data. But delaying trial results by one year, as Northwest Bio has done, is highly unusual, experts say. Investors can sometimes be kept out in the cold for too long, and patients left wondering whether an experimental treatment may one day be deemed effective.
So no one can think of a trial that’s delayed their results by a year?
AstraZeneca did for it’s PD-L1 MYSTIC study. I don't know how long they delayed it for but I know they delayed it. But Adam probably forgot them.
https://www.fiercebiotech.com/biotech/astrazeneca-delays-pd-l1-data-rejig-late-phase-program
Quote:“It’s the only time I can recall this happening in my career,” O’Rourke said.
O’Rourke forgot them too.
Quote:A DCVax study investigator, Dr. Tobias Walbert of the Henry Ford Health System Hermelin Brain Tumor Center, is also frustrated by the lack of updates from Northwest Bio. “No one really knows what’s going on. The study appears to be in limbo,” he said.
Cue Adam to the phone, he calls Dr. Walbert (who actually is a PI for the trial), who states no one knows what’s going on. If he’s a co-author, then he knows what’s going on, he just ain’t telling Adam. If he’s not, well then too bad for him. Remember I did suspect Adam was calling these people.
Quote:Northwest Bio has long denied that any interim look at the Phase 3 returned a futility verdict on DCVax. The company did not respond to a series of questions submitted for this article.
lol, like they are going to tell Adam anything. By the way, the subject of a futility verdict on DCVax has been discussed forever here. If one thinks a futility recommendation was made, I’d consider looking at who would make such a futility recommendation. Then, like with Dr. O’Roarke, I’d look to see what they might stand to gain by making it. Just saying.
Quote:But executives, speaking at an annual shareholder meeting on Jan. 21, reportedly shifted their priorities away from a timely reporting of study results.
According to multiple accounts of that meeting, the company is now focused on writing a scientific paper that will describe blended survival data collected from all brain tumor patients in the study, regardless if they were treated initially with DCVax or the current standard of care. (The study allowed control arm patients to cross over and receive DCVax when their tumors started growing again.)
Okay, he reported something accurately.
Quote: “The total lack of transparency is really unique. We work with a lot of companies and have a big clinical trial program, but I have never seen anything like this.”
DR. DON O’ROURKE, ENROLLED BRAIN TUMOR PATIENTS INTO NORTHWEST BIO’S STUDY
Consider the source people. This is coming from a big CAR T fan here who is NOT a PI for this trial.
Quote:Not everyone agrees with the approach. Dr. Vinay Prasad, an oncologist and assistant professor of medicine at the Oregon Health and Science University, believes Northwest Bio is merely trying to misdirect people away from the fact that DCVax does not work. Prasad has no ties to Northwest Bio and did not participate in the DCVax study.
“As a general rule, when you see endpoint switching, when you see delays in reporting results, when you see a company declining to unblind a study after the sufficient progression-free survival events are reached, and when you hear talk of taking a randomized trial and making a historical comparison — it is hard not to reach the conclusion that a product is more than likely an abject failure, the data are negative, and these efforts are merely a desperate attempt to salvage something,” Prasad said.
I can’t find this quote attributed to Prasad elsewhere, so it would seem he said it directly to Adam. I had thought Adam and Prasad didn’t get along so I’d initially suspected he’d found this quote in another article and used it, because Prasad is pretty well known for endorsing this perspective.
But I will point out that Dr. Prasad also was interviewed back in October 2016, and that he stated that when a trial is based on the rate of death (OS), if it takes longer for people to die, guess what? It’ll take longer to generate the result.
Here's what the outside cancer expert Prasad said (it's actually pretty interesting),
Quote:I hear that point a lot. Does waiting for survival take a very long time? That’s built into this question. That’s actually, to some degree—I hate to say it—it’s kind of a fallacy. And I’ll tell you why. The time it takes to generate a statistically positive result is, in some way, contingent on the rate of the event, which is death in this case. And, it is contingent on the rate of death; the longer that takes to happen, the longer it takes to generate the result. But it is also contingent on the sample size, and many modern trials have huge sample sizes.
We’ve looked at many of the oncology trials, and these trials that are being run in oncology are huge trials. We’re running oncology trials that are so powerful, they can detect survival benefits in a very short period of time. They are often overpowered to detect trivial differences.
The other thing this is all contingent upon is which indications do you develop cancer drugs for first? I think it is a mistake to think the manufacturers’ intent is to bring the drug to market as fast as possible. Manufacturers’ incentive is to bring the drug to market with as large a market share as possible. And in doing so, they often make decisions to chase a surrogate, even if that takes a longer period of time for a large indication. We have some examples of drugs that could have been brought to market even faster if we went for second rather than first line in a particular cancer.
So where should we allow surrogate endpoints? I think we should allow them in cases that are dire, where without a drug approved on a surrogate, people will pass away in a short period of time. I’m okay with them when there are a few other treatment options, for people who have very few options, like melanoma maybe five, six years ago. That’s where you want an accelerated approval. There’s literally nothing else we have to give people with that condition.
https://www.managedcaremag.com/archives/2016/10/conversation-vinay-prasad-md-first-do-no-harm-you-must-start-good-evidence
So back to Adam’s recent hit piece.
Quote:DCVax is a bespoke vaccine made from immune system sentinels called dendritic cells that are harvested from the blood of patients. These immune cells are exposed to a sample of each patient’s brain tumor in a lab. When re-injected into the patient, the trained dendritic cells, now known as DCVax, are supposed to find and kill cancer cells.
Yawn.
Quote:The challenge with this approach is that cancer cells have developed myriad ways to hide from or fight off dendritic cells, even when exposed to tumor targets in a lab. Similar vaccines developed by other biotech companies have failed. Dendreon’s prostate cancer vaccine Provenge is the sole exception, but the company eventually went bankrupt because the product could never overcome complaints about its cost or skepticism from doctors about its efficacy.
Uh huh. Blah, blah. But wait, Adam thought Rindo was going to do fabulously targeting the same EGFRv3 that Dr. Don is targeting with his CAR T GBM treatment. And we all know how Rindo turned out. And I thought Provenge was still being used, or did I miss something?
Quote:“The notion of treating patients with an individualized dendritic cell vaccine is not something people are endorsing right now,” said Penn’s O’Rourke. “The cancer immunotherapy field has moved on to checkpoint inhibitors and engineering of T cells.”
No surprise there. Of course Dr. Don thinks that.
But I have to ask, since when did the industry back dendritic cells? I also want to remind you that phRMA did feature this ad in late 2017, so I’m kinda thinking they are thinking they may be moving on to dendritic cells. I'll just feature their ad again here in my post. :)
Quote:The company hopes these blended survival data, compared against historical survival data published in the medical literature, will show DCVax helps brain tumor patients live longer and provide clinical evidence that could support the product’s approval. Northwest Bio is seeking to have the paper published in a medical journal.
Finally, Adam gets it.
Quote:Northwest Bio has been working on its experimental DCVax therapy for almost two decades, or roughly twice as long as most drugs take to move from discovery to regulatory approval.
Unfortunately, it takes awhile, as Dr. Prasad forgot he said earlier, it takes longer when every one is living longer.
Quote:The current DCVax Phase 3 clinical trial is now in its 10th year. By comparison, Celldex Therapeutics finished a randomized, controlled Phase 3 study of its own brain tumor vaccine in a little more than four years. The Celldex study enrolled twice as many patients as Northwest Bio’s DCVax study. It also failed.
Well a lot of us here kinda predicted Celldex would eventually fail, right? Their vaccine killed off the EGFRv3 protein, but so what? The tumor just came right back without it.
Quote:In August 2015, drug regulators placed a clinical hold on the DCVax study, preventing Northwest Bio from enrolling new brain tumor patients. (Treatment was allowed to continue for patients already in the study.) Northwest Bio never disclosed the reason for the clinical hold — another sharp departure from the norm, particularly for a publicly traded biotech company. Material events involving clinical trials are usually disclosed with more transparency.
Material events that could effect biases in blinded clinical trials are not usually disclosed, of course, unless they are bad. So I’m going out on a limb here, but… it must not have been bad. Or rather, it probably turned out not to be bad. Though there may have been a few involved who were bad seeds maybe even receiving honoraria that really tried to push the concept that it was. I wonder if there were, were they taken out of the loop and no longer had access to the information? Just a WAG.
Quote:The Food and Drug Administration lifted the hold in February 2017 — 18 months later — but in exchange, Northwest Bio agreed not to recruit any additional patients, meaning the study fell short of its enrollment goal.
Quote:Wrong, wrong, wrong. Now please don’t tell me Adam used ex and Avii as his “outside cancer expert" sources? lol. Anyway, NWBO announced on December 8 that they believed the “potential benefits that could be obtained from enrolling the final 17 patients would not be worth the time it would take, as the process of re-starting and re-training the sites (including through Institutional Review Board renewals) for further enrollment would take months, followed by further months for the recruitment itself.” Then on Feb 6, 2018, almost two months later, they announced the halt was lifted. My guess is that the FDA saw the light, and whatever might have been promulgated by people who might have been receiving honoraria who may have had a conflict of interest, or two, was finally chewed up and spat out. IMO
Quote:And now another year has passed. Inexplicably, Northwest Bio has become less communicative.
Yes… although the ASM note did provide us with some new insights. Adam too, but he, as usual, misunderstood them when he reported them.
Quote:“I don’t know what happened to the clinical trial since it was halted,” said Dr. Jana Portnow of the City of Hope National Medical Center in Duarte, Calif.
Hahahahaha. Dr. Portnow is a PI for the P3 trial. Her answer could be true, or it could be what she felt was the appropriate answer to give Adam who was obviously calling the PIs in the trial.
Quote:For investigators like O’Rourke, the company’s reluctance to analyze the clinical trial has only one likely explanation.
“I don’t think DCVax will wind up being the answer.”
Of course, O’Rourke is not an investigator in the DCVax-L trial so how would he know?
I’ll instead take the opinions of the 65 co-authors on the upcoming article over his. I’m sure this outside cancer expert Dr. Don O'Rourke has absolutely no idea what is going on with the DCVax-L trial.
And that's it in all its not very exciting entirety. :)
https://www.statnews.com/2018/02/15/northwest-bio-clinical-trial/?utm_source=STAT+Newsletters&utm_campaign=42879d981d-Readout&utm_medium=email&utm_term=0_8cab1d7961-42879d981d-150144869
Thanks for all your DD Larry.
Cashed in warrants?
That money goes directly to the company doesn't it?
yes, i just glanced at it. probably is
I was at ASM. I got no guarantees.
I am sure it is coming.
I just don't know when.
Funny when I first bought in in 2011, I thought it would be soon.
I guess it is all in perspective.
The earth is 4.5 billion years old. NWBO news will be soon by comparison.
Real good news, for the longs, on the way per ASM. IMO
Not without real fact based news*.
*Not a financing or shelf raise PR.
Should be a good day for longs. Seattle Conference leaks ? Publication this weekend ? No rest for shorts today and this weekend. NWBO could rocket upwards anytime. IMO
There is no question in my mind...
... that at ASM, Linda, in discussing the data review each spring, concluded they already knew they had a home run... and that by waiting... it was only to see how much "additional home run" they would get.
One could assume their will be another gathering of data this spring before they conclude the trial, IMHO.
Not that I liked hearing that, but that was what was insinuated.
Quote:Pretzel Logic — Steel Dan
LoL
She has directly related they already hit a home run from a blinded perspective; however, it’s comical watching people rely upon Alice in Wonderland, or torture isolated phrases to suggest an additional home run means no home run was already hit. Good luck selling that to an impartial audience.
Let’s review her statements regarding this issue again, this time with feeling. Please read through the end.
First part.
Quote:
What we do is, we look, and all we're allowed to see is blinded data, so we're looking at aggregate blinded data. In immunotherapy, the big focus is the so-called long tail of the survival curve. That is the HOME RUN. And what it means to have the long tail, is that the survival steps down, and when people continue to live, the tail goes way out here to the right. If a treatment achieves a long tail, that's the HOME RUN. I mean, part of it is the SLOPE of the graph, that's great too. But the big HOME RUN is the long tail. And you're seeing that being talked about with all of these therapies... with checkpoint inhibitors, everyone is super-excited because something like anywhere from 12 to 20% of the patients who respond in the first place are in a long tail and go for a couple of years. What people don't generally clarify is that even in the best case of cancers like melanoma where you're talking about a 25% response rate, you're talking about 25% of the 25%, talking about like 5% of the total participants in the trial. If some treatment were to come along and have 20 to 25% of the total patients in the trial, that would be considered a very large tail, and the question is how big and how long. That's what we want to see, and that's what you as shareholders should want to see. We share your anxiousness like it's Christmas morning. But when we stop the trial and unblind, the data collection for the purposes of the trial stops. After that, we will never know the full extent of the long tail. The long tail is the key focus
.
Follow up:
Quote:As we reported in ASCO last year, a huge number of patients, way more than expected, were still alive. We have to weigh that... how much of an ADDITIONAL HOME RUN would we get if we continue vs. going with what we have now.
You add that to Dr. Bosch (also of NWBO management) stating on June 5, 2017 that the OS event rate decreased drastically down to two events per month in the months leading up to June 5, 2017, and you obviously have the turning into the blinded tail. Then they get updated on survival as time runs along.
LP clearly wanted people to know they believe they have two home runs in slope and tail -- blinded of course. In addition to that the third leg of the stool talked about frequently is that everyone appears to be living longer.
Let's review.
1. "Great" slope. Home run.
2. Long tail. Home run still leaving the park. (also way more people alive than expected)
3. Early longevity apparently from entire group. (everyone seems to be living longer)
All blinded of course.
When you add these three things together, if accurate, one invariably must conclude the median has shifted to the right.
What a shame.
When for just 10% of your original investment ($6000.00) you could have averaged down to $1.40ish. Certainly in the money when the article comes out.
OH SORRY, I SHOULD HAVE TRANSLATED...
WHAT A SHAME.
WHEN FOR JUST 10% OF YOUR ORIGINAL INVESTMENT ($6000.00) YOU COULD HAVE AVERAGED DOWN TO $1.40ISH. CERTAINLY IN THE MONEY WHEN THE ARTICLE COMES OUT.
IM STILL LONG 10,000 SHARES @ $6.45
JUST GLAD I NEVER AVERAGED DOWN
HOPING IM WRONG BUT I REALLY THINK L/P SCAMMED ALL US LONGS
https://weather.com/weather/tenday/l/USFL0316:1:US
Versus
https://weather.com/weather/tenday/l/USMD0034:1:US
Where would you rather be?
Thanks Hankman, no reflection upon you but I find NWBO’s willingness to duck out of London and San Diego ridiculous now that they are apparently not ducking out of Miami even though, as you infer, they will still be awaiting disclosure of interim blinded data. I guess the sands of Miami call, since they are sending five people there to umm......await disclosure of interim blinded data? It was hard to write this without expletives.
Actual footage of Les at last ASM.
What he did to the guy trying to record the meeting...
Better yet conference it on the phone. No guts no glory!
Easier to ask forgiveness than permission.
Hopefully they will allow audio recording devices.
I will try. Not the greatest note taker.
Please take good notes and post the transcript, for those of us unable to make it.
Got it.. will see what I can do.
Just like NWBO, no promises. lol
Hi Diamondjim61,
Like most Longs, I believe the status of the DCVax-L Ph III is the most important item. You probably have your list of questions and this post may not have anything new for you.
Just one suggestion: If they are not able to provide the status (no PR beforehand), they may be able to say why they are not providing it and/or when they might be able to provide it.
Some refinement could include:
- the number of OS events,
- the planning/timeline of top line data release,
- the planning/timeline of the publication,
- the approach to a potential approval with the FDA (and the other three countries),
- the reason for the screening halt and its lift,
- the start of the DCVax Direct trial
I won't be able to attend the meeting.
Best of luck to Patients, NWBO, Longs.
Hope to see you there beartrap...
Will I recognize you from your Grizzly fur coat? lol
Diamond, there is a chance that I may go again this year. However, Sunday my husband and I had planned to be moving to our new house. But that will be going on for a week or two. We are still trying to decide if I can take the time to go. If so I will look for you. You are correct, in the past they give each person one question plus a follow up question or two. Sometimes we’ve gone around the room several times. They have always been very cordial toward us. I also had the chance to speak privately to Les and his wife last year, so it is well worth going. Linda and the others are very careful not to release any information that has not already been discussed publicly, FYI.
I will see what I can do to get your questions answered on Sunday.
Of course, as always with NWBO, no promises... just stay tuned.
These are two of the most immediate questions that I (probably we all) would like to have answered at the ASM if not already known by Jan 21, aside from the ultimate question of the success of PIII.
1) When and in what journal is the awaited paper to be published?
2) What will be the trigger for deciding when to unblind the PIII? (What are they waiting for now, given that both endpoints have been reached!)
I will be attending along with some friends.
If I remember from some other people attending it was basically a one question per attendee type of thing... if at all.
This is absolutely INSANE!!!
Question for the board... is anything planning to attend the ASM in person in DC? Would it make sense to either develop a list of topics or questions to pose the board at that meeting? Even little things like these meetings are strange trojan horses that need some explanation. Might be good to even have an offline discussion to put questions together ahead of the meeting without potential board viewing of this board. Thoughts?
I was agreeing with you.
I was saying it isn't a load of crap, it is true what you said.
Then somebody by all means get a copy of the list and show the 10s of thousands of retail names on it.
You won't, because you can't.
Stock in street name is not listed under the retail client.
Well, at least that is how it works in the real universe.
No problem Flip.
Wasn't sure if you were talking about me or someone else. lol
I suffer from acronym dyslexia. Don't judge me.
It isn't. It is true.
Confirmed it with TC already.
What a load of crap.
Me too.
JD is attending the ASM.
My broker has the day off on Monday.
You can make an appointment with Northwest to view the shareholder list in their office in Bethesda MD though.
Call your broker Monday and insist on having the number of voting shares listed. We should all do this. I am suprised that NWBO does not insist on this Coffer Black what do you say